HIV-2 is a nonpandemic form of the virus causing AIDS, and the majority of HIV-2-infected patients exhibit long-term nonprogression. The HIV-1 and HIV-2 envelope glycoproteins, the sole targets of neutralizing antibodies, share 30 to 40% identity. As a first step in understanding the reduced pathogenicity of HIV-2, we solved a 3.0-Å structure of an HIV-2 gp120 bound to the host receptor CD4, which reveals structural similarity to HIV-1 gp120 despite divergence in amino acid sequence.
H
uman immunodeficiency virus type 1 (HIV-1) remains a threat to global public health. With no vaccine available, it disproportionately causes AIDS in the developing world. While the related virus HIV-2 is capable of generating full-blown AIDS, infection rates are more localized and on the decline (1) (2) (3) (4) . In contrast to patients infected with HIV-1, the majority of HIV-2-infected individuals remain asymptomatic, with low plasma viral loads and normal CD4 ϩ T cell counts (5) (6) (7) . HIV-2 is a robust immunogen in natural infection, and patients readily make high-titer, broadly reactive, and strongly neutralizing antibodies against primary strains, something rarely seen in HIV-1 infections (1-3). In addition, HIV-2 appears slower to evolve the neutralization-resistant variant strains commonly found in HIV-1 infections (3, 8) . The rate of mother-to-child transmission is also much lower for HIV-2 (9), and differential neutralizing activities found in patients dually infected with HIV-1 and HIV-2 suggest the presence of distinct and divergent immune responses against these related viruses (10) .
The bulk of current investigative efforts are focused on HIV-1 due to its higher virulence and transmissibility. However, the immune response in the context of HIV-2 infection may provide a natural model of effective HIV control. While HIV-2 is not an attenuated virus, infected patients seem to naturally exhibit characteristics of a desired response to an effective therapy against HIV. Therefore, a deeper understanding of the immune response against HIV-2 could provide insight into how to elicit a similar response against HIV-1. HIV-1 and HIV-2 share 30% overall sequence identity and 40% amino acid identity in their envelope (Env) glycoprotein gp160 (1, 2, 11) , which is the sole target of neutralizing antibodies. Through structural studies of broadly neutralizing antibodies against HIV-1, these antibodies have been shown to target a variety of epitopes on the gp120 and gp41 subunits of HIV-1 gp160 (12) but do not generally cross-react between HIV-1 and HIV-2 (2, 13). Some HIV-1-induced CD4-induced (CD4i) antibodies, which bind to the coreceptor binding site exposed via a CD4-induced conformational change (14) , cross-react to neutralize several HIV-2 strains (13), suggesting structural similarity in this portion of HIV-1 and HIV-2 Env. However, some HIV-2 isolates can enter cells in a CD4-independent manner (15) , leading to the hypothesis that HIV-2 may have a more open coreceptor binding domain (3) .
Insights gained from the HIV-2 model of elite viral control may inform prophylactic and immunogen design for both forms of HIV. However, to date, no three-dimensional (3D) structures of HIV-2 Env have been reported. To investigate potential explanations for its decreased pathogenicity and increased immunogenicity compared with HIV-1 Env, we solved a 3.0-Å crystal structure of an HIV-2 gp120 core from the ST strain (gp120 ST ) (16) in complex with the first two domains of the host receptor CD4 (sCD4) and compared the structure to HIV-1 and SIV gp120 and CD4/gp120 structures.
A gene corresponding to HIV-2 gp120 ST (Los Alamos HIV sequence database [http://www.hiv.lanl.gov]) was modified based on the HIV-1 gp120 core used for crystallographic studies (11, (17) (18) (19) . Core gp120 ST contained deletions of the V1/V2 and V3 variable loops, 15 residues of the C terminus (11) , and a mutation (T89I) of a conserved potential N-linked glycosylation site (PNGS) distal from predicted binding interfaces (Fig. 1) . Core gp120 ST and sCD4 were expressed and purified as previously described (20, 21) and then cocrystallized via sitting drop vapor diffusion in a 1:1 mixture with 0.15 M DL-malic acid 7.0, 0.1 M imidazole (pH 7.0), and 22% polyethylene glycol (PEG) MME 550. Crystals were cryopreserved in Fomblin Y (Sigma), and 3.0-Å diffraction data (as determined by CC 1/2 [22] ) were collected at the SSRL beamline 12-2 and processed using XDS (23) ( Table 1) . Structure determination was performed by molecular replacement in Phaser (24) using structures of HIV-1 gp120 CAP210 (PDB code 3LQA, chain G, 35% identical) and sCD4 D1D2 (2NXY, chain B, 100% identical) as search models. (Molecular replacement using the structure of an SIV gp120 [2BF1; 72% identical to gp120 ST ] as a search model yielded no solutions.) Manual rebuilding guided by simulated annealing composite omit maps calculated using CNS (25) or Phenix.autosol (26) to minimize model bias (27) was performed using COOT (28) . Iterative rounds of refinement were performed using Phenix.refine (26) and Refmac (29) within the PDB_REDO server (30), including but not limited to rigid body, group B factor, translation, libration, and screwrotation (TLS), real-space, and Rosetta-guided refinement algorithms (31, 32) ( Table 1) .
The HIV-2 core gp120 ST structure (numbered according to the SIVmac239 convention [33] ) comprises 23 ␤-strands (␤1 to ␤23), five ␣-helices (␣1 to ␣5), five loop regions (A to E), truncated variable loops V1 to V3, and disordered loops V4 and V5 (Fig. 1) . In comparisons with available HIV-1 and SIV gp120 structures, we found that the gp120 ST structure was more similar to gp120 structures from HIV-1 (PDB code 2NXY [34] , 4P9H [20] , 3LQA [21] , 2B4C [35] , 1RZK [36] , 3U7Y [37] ) than to the structure of SIVmac32H gp120 (2BF1 [19] ), despite sharing only ϳ35% sequence identity with HIV-1 gp120s compared with 72% identity with SIVmac32H gp120 (11, 19) (Fig. 1C and 2D) . Indeed, the overall architecture of HIV-2 gp120 ST was nearly identical to both liganded and unliganded (PDB code 3TGT [17] ) HIV-1 gp120 cores, with secondary structure elements comprising the inner and outer domains adopting common conformations (Fig. 1) . When superimposed with HIV-1 gp120 core structures using sequence-based alignment in PyMOL (38) , the core gp120 ST structure yielded root mean square deviation (RMSD) values of 1.3 to 1.6 Å (Fig. 2) . In contrast, the HIV-2 gp120 ST structure aligned poorly with the structure of unliganded SIVmac32H gp120 (19) (RMSD ϭ 5.6 Å for 230 C␣ atoms), and the ␤-strands comprising the bridging sheet were shifted by 13 to 25 Å, the V1/V2 stems were shifted by ϳ27 Å, the ␣1 helix was shifted by 15 Å, and the threestranded ␤-sheet at the C terminus was offset by a 90°rotation (Fig. 2A) . We therefore used HIV-1 core gp120 structures for comparisons with HIV-2 gp120 ST .
Analysis of structural and sequence conservation between gp120 ST core and the seven most similar HIV-1 gp120 core structures in the PDB (4DVR, 3TGR, 1G9N , 3U7Y, 4JM2, 2NY0, and 1GC1) using ENDScript (39) showed high degrees of structural conservation in most ordered regions. Notably, the coreceptor binding footprint, which comprises the bridging sheet and surrounding residues, showed no major differences between gp120 ST and HIV-1 gp120s. In the HIV-2 gp120 ST structure, six conserved disulfide bonds superimposed with their counterparts in HIV-1 gp120 core structures. Eight PNGSs showed ordered sugar residues (Fig. 2) . Only two (N262 HXB2 and N386 HXB2 ) are also PNGSs in HIV-1 gp120s.
It has been postulated that HIV-2 has a more open V3 loop conformation than HIV-1 due to the HIV-2 V3 loop having fewer PNGSs (40) . Core gp120 ST has a truncated V3 stem with the same number of residues as the truncated stem in HIV-1 gp120 93TH057 (3U7Y) and 10 more residues than the V3 stem in HIV-1 gp120 HXB2 (2NXY). The ST and HIV-1 93TH057 V3 stems of equal length were superimposed with an RMSD of 0.46 Å. Thus, characterizing differences in this region between HIV-1 and HIV-2 would require future comparison of structures with intact and ordered V3 loops. The V4 and V5 loops, which are shorter and less glycosylated in HIV-2 than in HIV-1, were completely disordered in the gp120 ST core structure. One of the most distinct structural differences between HIV-2 and HIV-1 gp120 is the extended loop E of HIV-2 gp120, which emanates from the junction between the ␣2 helix and ␤14 strand in the gp120 ST core structure. In alignments with loop E from HIV-1 gp120 (Fig. 2C) , ST loop E was 3 to 5 residues longer and featured a turn not seen in HIV-1 gp120 structures.
Superposition of the gp120 ST /sCD4 structure on three HIV-1 gp120/sCD4 structures revealed no notable global differences in the orientation of sCD4 binding to gp120 ST (RMSD values of 2 to 2.1 Å after aligning 350 to 380 C␣ atoms from gp120 and CD4) (Fig. 3) . HIV-2 and HIV-1 gp120s share the same core interactions with CD4, represented on CD4 by residues 40 to 60, including the CЉ strand and residues F43 CD4 and R59 CD4 , and on gp120 by the CD4 binding loop, the F43 CD4 -binding pocket, and the D386 gp120-ST /368 gp120-HXB2 (Fig. 4) . However, gp120 loop D, which makes close contacts with sCD4, differed greatly between HIV-1 and HIV-2 (Los Alamos HIV sequence database [http://www.hiv.lanl.gov]). Differences included overall sequence, conformation, and glycosylation pattern. HIV-1 and HIV-2 gp120 residue 280 gp120-HXB2 /295 gp120-ST features a highly conserved asparagine, which is the N-terminal residue of a PNGS in nearly all HIV-2 strains but never in HIV-1 strains (Los Alamos HIV sequence database [http://www.hiv.lanl .gov]). Instead, HIV-1 strains usually have a PNGS at position 276 gp120-HXB2 . The different loop D sequences are reflected in several differences in the gp120-sCD4 interaction. HIV-1 loop D and the pre-V5 ␤23 strand interact with CD4 residues 29 to 35, but these interactions are absent in HIV-2. Conversely, HIV-2 gp120 has CD4 interactions that do not occur in HIV-1: loop D residue R293 gp120-ST interacts with E87 CD4 and D88 CD4 . Also, the BC loop of CD4 (residues 19 to 25), which in other CD4 structures (11, 20, 36) (including structures of CD4 alone [41] [42] [43] ) is packed against the CD4 DE loop, is displaced ϳ6 Å toward HIV-2 gp120, interacting with E84 gp120-ST and N79 gp120-ST near the beginning of the ␣1 helix.
Given the difference in pathogenicity between HIV-1 and HIV-2 (3) and the highly distinct unliganded SIV gp120 structure (19), we expected larger differences between the gp120 structures of the two human viruses. Because the unexpected similarities between HIV-1 and HIV-2 gp120s do not explain the difference in virulence between HIV-1 and HIV-2 (1-4) , the decreased virulence of HIV-2 may relate to structural difference outside the gp120 core or to other differences between the two classes of virus. If decreased virulence is related at least in part to Env structure, differential immune activation could result from differences in the variable loops, which are truncated or disordered in gp120 core structures, and/or fewer Nlinked glycans resulting in decreased glycan shielding of the HIV-2 V3 and V4 loops (40) . As demonstrated in X-ray and EM structures of trimeric HIV-1 Env (44-48), quaternary interactions outside the context of monomeric gp120 likely also play key roles in the behavior of HIV-2. Due to the robust neutralizing antibody response to HIV-2 (1-3), it is likely that differences in pathogenicity are due, at least in part, to the role of the Env glycoprotein. This is encouraging for the future growth of HIV-2 knowledge, as the HIV field has long been focused and is well equipped for conducting comprehensive structural studies of the interactions between Env and its binding partners. Further X-ray crystallographic or EM studies involving neutralizing antibodies against HIV-2 Env should provide greater insight into this intriguing model of viral control. there are residues that are contacted by only HIV-1 or HIV-2 gp120. The CCP4 program AREAIMOL (mode DIFFMODE COMPARE) was used to calculate the per-residue difference in accessible surface area (1.4-Å probe radius) for CD4 upon complex formation with Env. HIV-1 coordinates were from PDB entry 1RZJ.
